



## **Cipla Board Announces Appointment of Samina Vaziralli onto the Board of Directors**

**India, Mumbai 9 July 2015:** Cipla, a global Indian pharmaceutical company is pleased to announce the appointment of Samina Vaziralli as executive director on its board effective 10th July 2015.

Samina Vaziralli is the daughter of Mr. M. K. Hamied, Vice Chairman of the Board of Cipla. She is part of the core leadership team and has been with the company since 2011. Samina graduated from the London School of Economics and Political Science with a MSc. in International Accounting and Finance and was previously with the investment management division of Goldman Sachs. Samina brings diverse experience of working in the United States, the United Kingdom, and more recently India.

Samina has played a significant role in the Company's ongoing transformation journey and has a strong understanding of both operating levers of the business today and key drivers for future growth and sustainability. She has been responsible for successfully incubating and shaping Cipla's Consumer Healthcare business as part of Cipla New Ventures. She has also recently taken on an expanded role leading global strategic alliances and enabling Cipla's people strategy and leadership development.

Welcoming her appointment as a director, **Mr. Adil Zainulbhai, Independent Director and Chairman of the Nomination and Remuneration Committee, Cipla Limited** said: "I am delighted to welcome Samina to the Board. She will reinforce the commitment and continuity of the Hamied family's involvement in Cipla. She will help drive Cipla to achieving its strategic vision."

On her appointment to the Board, **Samina Vaziralli** said: "I am happy to be in position to contribute to steering Cipla as a member of the Board at this exciting moment. Cipla has made huge strides in the last couple of years in taking the business and the brand into new areas and I look forward to working with our leadership team on executing our strategy."

The Board of Directors of the Company at its meeting held on 9th July 2015 approved the divestment of its consumer healthcare business to a wholly owned subsidiary that is proposed to be incorporated. This exciting development gives scope to develop the division as a strong, customer focussed business with operational independence and the ability to attract and develop expertise which is more FMCG-oriented. The vision is to improve the lives of Indian consumers, making full use of Cipla's strengths in bringing good science to good medicine, while also leveraging its market outreach and equity with the Indian healthcare system. The business will focus on opportunities arising from the shift towards wellness and self-care.

Commenting on these developments **Subhanu Saxena MD and Global CEO, Cipla** said: "I am personally delighted at having Samina on the Board as she will contribute greatly to the strategic direction of the Company. I am also very pleased that the Company is making such a

positive move into the Consumer Healthcare space. There is a very good opportunity for Cipla, a Company which has contributed immensely to patient health, to also contribute to patient wellness. The over-the-counter business means that we can speak to the patient directly and help them to foster good health and illness prevention.”

This division recently launched its first product Nicotex, a gum which helps smokers quit the habit. This product is a switch from our prescription business and has had a very successful launch in the South of the country.

### **About Cipla Limited**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems.

### **Media Contacts:**

#### **Corporate Communications**

Charlotte Chunawala

Mobile: +91 7506257377

E Mail: [charlotte.chunawala@cipla.com](mailto:charlotte.chunawala@cipla.com);

Pallavi Golar

Mobile: +91 9833641788

E Mail: [pallavi.golar@cipla.com](mailto:pallavi.golar@cipla.com)